Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of DGX-001 in Healthy Volunteers
NCT05121831Phase 1Completed
- Sponsor
- Viage Therapeutics
- Start
- Feb 2022
- Primary completion
- Nov 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DGX-001 in major depressive disorder (MDD) (8 cohorts), sponsored by Viage Therapeutics. Primary endpoints: Number of treatment-emergent adverse events, Severity of treatment-emergent adverse events and 3 more. Started Feb 2022; status: completed.
02
Drugs
DGX-001
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05121831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121831.